Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: A double-blind, randomized, placebo-controlled study
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treatment with omega-3 fatty acids and fenofibrates reduces serum triglyceride levels, but few studies have compared the effect of these agents on liver fat. OBJECTIVE: The aim of the EFFECT I trial (NCT02354976) was to determine the effects of free omega-3 carboxylic acids (OM-3CA) and fenofibrate on liver fat in overweight or obese individuals with non-alcoholic fatty liver disease and hypertriglyceridemia. METHODS: Seventy-eight patients were randomized to receive oral doses of 4 g OM-3CA (n = 25), 200 mg fenofibrate (n = 27), or placebo (n = 26) for 12 weeks in a double-blind, parallel-group study. Liver proton density fat fraction (PDFF) and volume, pancreas volume, and adipose tissue volumes were assessed by magnetic resonance imaging. RESULTS: Changes in liver PDFF at 12 weeks were not significantly different across treatment groups (relative changes from baseline: placebo, +4%; OM-3CA, -2%; and fenofibrate, +17%). The common PNPLA3 genetic polymorphism (I148M) did not significantly influence the effects of OM-3CA or fenofibrate on liver PDFF. Fenofibrate treatment significantly increased liver and pancreas volumes vs placebo treatment, and the changes in liver and pancreas volumes were positively correlated (rho 0.45, P = .02). Total liver fat volume increased significantly in patients using fenofibrate vs OM-3CA (+23% vs -3%, P = .04). Compared with OM-3CA, fenofibrate increased total liver fat and liver volume. Serum triglycerides decreased with OM-3CA (-26%, P = .02) and fenofibrate (-38%, P < .001) vs placebo. In contrast to OM-3CA, fenofibrate reduced plasma docosahexaenoic acid levels and increased plasma acetylcarnitine and butyrylcarnitine levels, estimated delta-9 desaturase activity and the concentration of urine F2-isoprostanes. CONCLUSIONS: OM-3CA and fenofibrate reduced serum triglycerides but did not reduce liver fat. Fenofibrate increased total liver volume and total liver fat volume vs OM-3CA, indicating a complex effect of fenofibrate on human hepatic lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Koves, T. R., Ussher, J. R., Noland, R. C., Slentz, D., Mosedale, M., Ilkayeva, O., Bain, J., Stevens, R., Dyck, J. R. B., Newgard, C. B., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.013 · Cited by 1,990
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408 · cited 1×
“In addition, severe hypertriglyceridemia, defined as serum TG levels of more than 10 mM (885 mg/dL), is associated with increased acute pancreatitis risk.(3,5,6) Initial management of hypertriglyceridemia typically involves altering the diet to reduce the intake of dietary fat, simple carbohydrates, and alcohol and in…”
BackgroundKoliaki, C., Szendroedi, J., Kaul, K., Jelenik, T., Nowotny, P., Jankowiak, F., Herder, C., Carstensen, M., Krausch, M., Knoefel, W. T., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.04.004 · Cited by 1,032 · cited 1×
“Similarly, in line with previous results in patients with NAFLD,(60) OM-3CA treatment reduced FGF21 levels; this may indicate an improved hepatic metabolism, given that high FGF21 levels are associated with NAFLD and mitochondrial dysfunction.(61) OM-3CA treatment, in contrast to fenofibrate treatment, resulted in sma…”
ResultEvaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline
Berglund, L., Brunzell, J. D., Goldberg, A. C., Goldberg, I. J., Sacks, F., Murad, M. H., & Stalenhoef, A. F. H. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3213 · Cited by 887 · cited 5×
“In addition, severe hypertriglyceridemia, defined as serum TG levels of more than 10 mM (885 mg/dL), is associated with increased acute pancreatitis risk.(3,5,6) Initial management of hypertriglyceridemia typically involves altering the diet to reduce the intake of dietary fat, simple carbohydrates, and alcohol and in…”
BackgroundInfluentialOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635 · cited 6×
“In addition, severe hypertriglyceridemia, defined as serum TG levels of more than 10 mM (885 mg/dL), is associated with increased acute pancreatitis risk.(3,5,6) Initial management of hypertriglyceridemia typically involves altering the diet to reduce the intake of dietary fat, simple carbohydrates, and alcohol and in…”
BackgroundInfluentialAdams, S. H., Hoppel, C. L., Lok, K. H., Zhao, L., Wong, S. W., Minkler, P. E., Hwang, D. H., Newman, J. W., & Garvey, W. T. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.103754 · Cited by 598
Omega-3 supplementation and non-alcoholic fatty liver disease: A systematic review and meta-analysis
Parker, H. M., Johnson, N. A., Burdon, C. A., Cohn, J. S., O’Connor, H. T., & George, J. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.08.018 · Cited by 569
Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512
Bjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490
Self-citationRosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.-E., Larsson, A., Johansson, L., Ahlström, H., Arner, P., Dahlman, I., et al. (2014) · Diabetes · doi:10.2337/db13-1622 · Cited by 429
Self-citationWhy do omega-3 fatty acids lower serum triglycerides?
Harris, W. S., & Bulchandani, D. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236363.63840.16 · Cited by 398 · cited 1×
“Omega-3 fatty acids reduce serum TG levels by decreasing VLDL production rates, while VLDL clearance rates are less consistently affected.(12,13) A meta-analysis of human interventional studies showed that omega-3 fatty acids decrease liver fat content in the absence of weight loss.”
BackgroundEriksson, J. W., Lundkvist, P., Jansson, P.-A., Johansson, L., Kvarnström, M., Moris, L., Miliotis, T., Forsberg, G.-B., Risérus, U., Lind, L., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4675-2 · Cited by 396 · cited 1×
“Plasma levels of acylcarnitines (L-acetylcarnitine, Lbutyrylcarnitine, L-octanoylcarnitine, and L-palmitoylcarnitine) and urine levels of nonesterified F2-isoprostanes (2,3-dinor-8-iso-prostaglandin-F2a and 8-iso-prostaglandin-F2a) were quantified by liquid chromatography/ mass spectrometry as previously described.(37)”
MethodSelf-citationShiri-Sverdlov, R., Wouters, K., Gorp, P. J. V., Gijbels, M. J., Noel, B., Buffat, L., Staels, B., Maeda, N., Bilsen, M. V., & Hofker, M. H. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.033 · Cited by 241
Fabbrini, E., Mohammed, B. S., Korenblat, K. M., Magkos, F., McCrea, J., Patterson, B. W., & Klein, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2622 · Cited by 192
Fibrates for primary prevention of cardiovascular disease events
Jakob, T., Nordmann, A. J., Schandelmaier, S., Ferreira-González, I., & Briel, M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009753.pub2 · Cited by 147
Rosenson, R. S., Wolff, D. A., Huskin, A. L., Helenowski, I. B., & Rademaker, A. W. (2007) · Diabetes Care · doi:10.2337/dc07-0015 · Cited by 117
Ip, C.-K., Jin, D.-M., Gao, J.-J., Meng, Z., Meng, J., Tan, Z., Wang, J.-F., & Geng, D.-F. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.04.228 · Cited by 43 · cited 2×
“Statins reduce LDL-C levels effectively, but there remains a residual CV risk associated with atherogenic dyslipidemia (low serum levels of HDL cholesterol [HDL-C] and high serum levels of TGs).(1,2) Mild to moderate hypertriglyceridemia, defined as serum TG levels of 2.”
Background
Research works printed but not linked: 41
- Karlson, 2016, A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia, Am J Cardiol, 117, 1444, 10.1016/j.amjcard.2016.02.011 · DOI · Paper page
- 2016, Vol. 2017
- Patel, 2016, Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia, Curr Opin Endocrinol Diabetes Obes, 23, 145, 10.1097/MED.0000000000000233 · DOI
- Davidson, 2016, The future of n-3 polyunsaturated fatty acid therapy, Curr Opin Lipidol, 27, 570, 10.1097/MOL.0000000000000353 · DOI
- Oscarsson, 2017, Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review, Lipids Health Dis, 16, 149, 10.1186/s12944-017-0541-3 · DOI · Paper page
- Cussons, 2009, Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy, J Clin Endocrinol Metab, 94, 3842, 10.1210/jc.2009-0870 · DOI · Paper page
- Vega, 2008, Effects of N-3 fatty acids on hepatic triglyceride content in humans, J Investig Med, 56, 780, 10.2310/JIM.0b013e318177024d · DOI · Paper page
- Scorletti, 2014, Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the WELCOME* study, Hepatology, 60, 1211, 10.1002/hep.27289 · DOI · Paper page
- Keating, 2011, Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus, Am J Cardiovasc Drugs, 11, 227, 10.2165/11207690-000000000-00000 · DOI
- Balasubramanian, 2010, Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content, Diabet Med, 27, 150, 10.1111/j.1464-5491.2009.02906.x · DOI
- Cree, 2007, Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment, Mech Ageing Dev, 128, 558, 10.1016/j.mad.2007.08.001 · DOI
- Bajaj, 2007, Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus, Diabetologia, 50, 1723, 10.1007/s00125-007-0698-9 · DOI
- Risérus, 2008, Activation of peroxisome proliferator-activated receptor (PPAR) delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men, Diabetes, 57, 332, 10.2337/db07-1318 · DOI · Paper page
- Harano, 2006, Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver, Liver Int, 26, 613, 10.1111/j.1478-3231.2006.01265.x · DOI · Paper page
- Huang, 2012, Sustained activation of PPARalpha by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice, FASEB J, 26, 628, 10.1096/fj.11-194019 · DOI · Paper page
- Waterman, 2002, Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities, Diabetes, 51, 1708, 10.2337/diabetes.51.6.1708 · DOI · Paper page
- Edvardsson, 2006, PPARalpha activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes, J Lipid Res, 47, 329, 10.1194/jlr.M500203-JLR200 · DOI
- Yan, 2014, Peroxisome proliferator-activated receptor alpha activation induces hepatic steatosis, suggesting an adverse effect, PLoS One, 9, e99245, 10.1371/journal.pone.0099245 · DOI
- Berglund, 2012, Three-dimensional water/fat separation and T2* estimation based on whole-image optimization – application in breathhold liver imaging at 1.5 T, Magn Reson Med, 67, 1684, 10.1002/mrm.23185 · DOI
- Schneider, 2012, NIH Image to ImageJ: 25 years of image analysis, Nat Methods, 9, 671, 10.1038/nmeth.2089 · DOI · Paper page
- Malmberg, 2017, SmartPaint: a tool for interactive segmentation of medical volume images, Comput Methods Biomech Biomed Eng Imaging Vis, 5, 36, 10.1080/21681163.2014.960535 · DOI
- Angulo, 2007, The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD, Hepatology, 45, 846, 10.1002/hep.21496 · DOI · Paper page
- Boberg, 1985, Platelet fatty acid composition in relation to fatty acid composition in plasma and to serum lipoprotein lipids in healthy subjects with special reference to the linoleic acid pathway, Clin Sci, 68, 581, 10.1042/cs0680581 · DOI · Paper page
- Gariot, 1983, Fenofibrate and human liver. Lack of proliferation of peroxisomes, Arch Toxicol, 53, 151, 10.1007/BF00302723 · DOI
- Gariot, 1987, Morphometric study of human hepatic cell modifications induced by fenofibrate, Metabolism, 36, 203, 10.1016/0026-0495(87)90177-6 · DOI
- Tailleux, 2012, Roles of PPARs in NAFLD: potential therapeutic targets, Biochim Biophys Acta, 1821, 809, 10.1016/j.bbalip.2011.10.016 · DOI · Paper page
- Kersten, 2014, Integrated physiology and systems biology of PPARalpha, Mol Metab, 3, 354, 10.1016/j.molmet.2014.02.002 · DOI · Paper page
- Koh, 2012, Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia, Atherosclerosis, 220, 537, 10.1016/j.atherosclerosis.2011.11.018 · DOI · Paper page
- Otto, 1996, Effects of n-3 fatty acids and fenofibrate on lipid and hemorrheological parameters in familial dysbetalipoproteinemia and familial hypertriglyceridemia, Metabolism, 45, 1305, 10.1016/S0026-0495(96)90252-8 · DOI
- Agheli, 1991, Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients, Br J Clin Pharmacol, 32, 423, 10.1111/j.1365-2125.1991.tb03925.x · DOI
- Fernandez-Alvarez, 2011, Human SREBP1c expression in liver is directly regulated by peroxisome proliferator-activated receptor alpha (PPARalpha), J Biol Chem, 286, 21466, 10.1074/jbc.M110.209973 · DOI · Paper page
- Yary, 2016, Serum n-6 polyunsaturated fatty acids, Delta5- and Delta6-desaturase activities, and risk of incident type 2 diabetes in men: the Kuopio Ischaemic heart disease risk factor study, Am J Clin Nutr, 103, 1337, 10.3945/ajcn.115.128629 · DOI
- Vessby, 1994, The risk to develop NIDDM is related to the fatty acid composition of the serum cholesterol esters, Diabetes, 43, 1353, 10.2337/diab.43.11.1353 · DOI · Paper page
- Gonzalez-Periz, 2009, Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins, Faseb J, 23, 1946, 10.1096/fj.08-125674 · DOI · Paper page
- Sun, 2016, Early prediction of developing type 2 diabetes by plasma acylcarnitines: a population-based study, Diabetes Care, 39, 1563, 10.2337/dc16-0232 · DOI · Paper page
- Xu, 2016, Liver and muscle contribute differently to the plasma acylcarnitine pool during fasting and exercise in humans, J Clin Endocrinol Metab, 101, 5044, 10.1210/jc.2016-1859 · DOI · Paper page
- Kobayashi, 2009, Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats, J Toxicol Sci, 34, 377, 10.2131/jts.34.377 · DOI
- Fernandez-Miranda, 2008, A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease, Dig Liver Dis, 40, 200, 10.1016/j.dld.2007.10.002 · DOI · Paper page
- Kei, 2014, Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia, Cardiovasc Ther, 32, 139, 10.1111/1755-5922.12072 · DOI
- Qin, 2015, Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin E2 in nonalcoholic fatty liver disease associated with hyperlipidemia: a randomized clinical trial, PLoS One, 10, e0133496, 10.1371/journal.pone.0133496 · DOI · Paper page
- De Caterina, 2007, N-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data, Diabetes Care, 30, 1012, 10.2337/dc06-1332 · DOI · Paper page
Cited by
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
Challenges and opportunities in NASH drug development
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M., & Alkhouri, N. (2023) · Nature Medicine · doi:10.1038/s41591-023-02242-6 · Cited by 353
Pancreatic β-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress
Dludla, P. V., Mabhida, S. E., Ziqubu, K., Nkambule, B. B., Mazibuko-Mbeje, S. E., Hanser, S., Basson, A. K., Pheiffer, C., & Kengne, A. P. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.130 · Cited by 344
Calle, R. A., Amin, N. B., Carvajal-Gonzalez, S., Ross, T. T., Bergman, A., Aggarwal, S., Crowley, C., Rinaldi, A., Mancuso, J., Aggarwal, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01489-1 · Cited by 219
Bergmark, B. A., Marston, N. A., Bramson, C. R., Curto, M., Ramos, V., Jevne, A., Kuder, J. F., Park, J.-G., Murphy, S. A., Verma, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059266 · Cited by 216
Metadata
- Authors
- Oscarsson, J., Önnerhag, K., Risérus, U., Sundén, M., Johansson, L., Jansson, P.-A., Moris, L., Nilsson, P. M., Eriksson, J. W., & Lind, L.
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 12
- Issue
- 6
- Pages
- 1390-1403.e4
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W2887902401
- Cited by
- 112
- References
- 21
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- AstraZeneca
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.